Sichuan Kelun Pharmaceutical Co., Ltd. (002422.SZ)
CNY 34.82
(-2.49%)
CNY 34.82
(-2.49%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 3.65 Billion CNY | 49.12% |
| 2022 | 2.19 Billion CNY | 22.62% |
| 2021 | 1.79 Billion CNY | 9.46% |
| 2020 | 1.63 Billion CNY | -17.12% |
| 2019 | 1.97 Billion CNY | 45.75% |
| 2018 | 1.35 Billion CNY | 17.23% |
| 2017 | 1.15 Billion CNY | 73.16% |
| 2016 | 668.05 Million CNY | 16.49% |
| 2015 | 573.5 Million CNY | -47.32% |
| 2014 | 1.08 Billion CNY | -5.21% |
| 2013 | 1.14 Billion CNY | 1.21% |
| 2012 | 1.13 Billion CNY | 7.04% |
| 2011 | 1.06 Billion CNY | 40.54% |
| 2010 | 754.4 Million CNY | 49.22% |
| 2009 | 505.55 Million CNY | 43.17% |
| 2008 | 353.1 Million CNY | 43.26% |
| 2007 | 246.47 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 1.27 Billion CNY | -10.02% |
| 2024 Q1 | 1.42 Billion CNY | 61.82% |
| 2024 Q3 | 797.78 Million CNY | -29.81% |
| 2023 Q1 | 1.12 Billion CNY | 225.02% |
| 2023 Q4 | 878.77 Million CNY | 22.07% |
| 2023 FY | 3.27 Billion CNY | 49.12% |
| 2023 Q3 | 719.91 Million CNY | -4.58% |
| 2023 Q2 | 754.47 Million CNY | -32.82% |
| 2022 Q1 | 333.46 Million CNY | -14.26% |
| 2022 Q4 | 345.53 Million CNY | -54.32% |
| 2022 FY | 2.19 Billion CNY | 22.62% |
| 2022 Q3 | 756.51 Million CNY | -0.89% |
| 2022 Q2 | 763.33 Million CNY | 128.91% |
| 2021 Q1 | 177.07 Million CNY | -48.11% |
| 2021 Q3 | 410.97 Million CNY | 19.86% |
| 2021 Q4 | 388.91 Million CNY | -5.37% |
| 2021 Q2 | 342.88 Million CNY | 93.63% |
| 2021 FY | 1.79 Billion CNY | 9.46% |
| 2020 FY | 1.63 Billion CNY | -17.12% |
| 2020 Q2 | 232.44 Million CNY | 385.48% |
| 2020 Q4 | 341.28 Million CNY | -12.12% |
| 2020 Q3 | 388.35 Million CNY | 67.07% |
| 2020 Q1 | 47.87 Million CNY | -72.75% |
| 2019 Q3 | 251.95 Million CNY | -44.12% |
| 2019 Q1 | 398.31 Million CNY | 90.46% |
| 2019 Q2 | 450.88 Million CNY | 13.2% |
| 2019 FY | 1.97 Billion CNY | 45.75% |
| 2019 Q4 | 175.73 Million CNY | -30.25% |
| 2018 Q1 | 385.02 Million CNY | -34.31% |
| 2018 Q4 | 209.13 Million CNY | -28.83% |
| 2018 Q3 | 293.84 Million CNY | -37.24% |
| 2018 FY | 1.35 Billion CNY | 17.23% |
| 2018 Q2 | 468.2 Million CNY | 21.6% |
| 2017 Q2 | 145 Million CNY | -39.18% |
| 2017 FY | 1.15 Billion CNY | 73.16% |
| 2017 Q4 | 586.14 Million CNY | 212.98% |
| 2017 Q3 | 187.27 Million CNY | 29.15% |
| 2017 Q1 | 238.4 Million CNY | 177.83% |
| 2016 Q4 | 85.81 Million CNY | -44.45% |
| 2016 FY | 668.05 Million CNY | 16.49% |
| 2016 Q1 | 229.33 Million CNY | 358.96% |
| 2016 Q2 | 198.42 Million CNY | -13.48% |
| 2016 Q3 | 154.48 Million CNY | -22.14% |
| 2015 Q4 | 49.96 Million CNY | -37.51% |
| 2015 FY | 573.5 Million CNY | -47.32% |
| 2015 Q3 | 79.95 Million CNY | -61.6% |
| 2015 Q2 | 208.2 Million CNY | -11.54% |
| 2015 Q1 | 235.36 Million CNY | 52.1% |
| 2014 Q3 | 323.92 Million CNY | -9.03% |
| 2014 Q1 | 254.01 Million CNY | 25.87% |
| 2014 FY | 1.08 Billion CNY | -5.21% |
| 2014 Q4 | 154.74 Million CNY | -52.23% |
| 2014 Q2 | 356.06 Million CNY | 40.18% |
| 2013 Q2 | 366.24 Million CNY | 63.15% |
| 2013 Q3 | 356 Million CNY | -2.8% |
| 2013 FY | 1.14 Billion CNY | 1.21% |
| 2013 Q4 | 201.8 Million CNY | -43.31% |
| 2013 Q1 | 224.48 Million CNY | -28.62% |
| 2012 Q3 | 326.03 Million CNY | 1.23% |
| 2012 Q1 | 172.21 Million CNY | -40.16% |
| 2012 Q4 | 314.48 Million CNY | -3.54% |
| 2012 Q2 | 322.07 Million CNY | 87.02% |
| 2012 FY | 1.13 Billion CNY | 7.04% |
| 2011 Q1 | 168.07 Million CNY | -31.88% |
| 2011 FY | 1.06 Billion CNY | 40.54% |
| 2011 Q4 | 287.78 Million CNY | -8.22% |
| 2011 Q3 | 313.55 Million CNY | 7.82% |
| 2011 Q2 | 290.81 Million CNY | 73.02% |
| 2010 Q3 | 215.04 Million CNY | 16.62% |
| 2010 Q2 | 184.4 Million CNY | 70.42% |
| 2010 Q1 | 108.2 Million CNY | -28.44% |
| 2010 Q4 | 246.74 Million CNY | 14.74% |
| 2010 FY | 754.4 Million CNY | 49.22% |
| 2009 Q4 | 151.2 Million CNY | 3.41% |
| 2009 FY | 505.55 Million CNY | 43.17% |
| 2009 Q3 | 146.21 Million CNY | 14.33% |
| 2009 Q2 | 127.88 Million CNY | 59.33% |
| 2009 Q1 | 80.26 Million CNY | 0.0% |
| 2008 FY | 353.1 Million CNY | 43.26% |
| 2007 FY | 246.47 Million CNY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Zhejiang Int'l Group Co.,Ltd. | 825.98 Million CNY | -342.401% |
| Zhejiang Zhenyuan Share Co., Ltd. | 113.04 Million CNY | -3132.582% |
| Hunan Jingfeng Pharmaceutical Co.,Ltd. | -104.37 Million CNY | 3600.824% |
| Hubei Guangji Pharmaceutical Co., Ltd. | -141.05 Million CNY | 2690.613% |
| Yifan Pharmaceutical Co., Ltd. | -882.71 Million CNY | 513.968% |
| Guangdong Jiaying Pharmaceutical Co., Ltd | 40.51 Million CNY | -8919.127% |
| Chongqing Lummy Pharmaceutical Co., Ltd. | -56.7 Million CNY | 6543.952% |
| Boai NKY Medical Holdings Ltd. | 585.23 Million CNY | -524.389% |
| Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. | 344.97 Million CNY | -959.254% |